Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing
2020-005518-16Phase 4Active
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in psoriatic arthritis (PsA), sponsored by Universitätsklinikum Erlangen. Primary endpoint: BOLD signal voxel count change at week 1 and week 12. Started Mar 2021; status: active.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2020-005518-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005518-16.